Trade
Basic
Futures
Futures
Hundreds of contracts settled in USDT or BTC
Options
HOT
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
NEW
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
NEW
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
NEW
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
Kehua Holdings: The controlling shareholder plans to transfer shares, and the stock will be suspended next Monday.
2025-08-15 09:16
After reviewing 35 years of A-share trends, what will happen after the Shanghai Composite Index reaches a ten-year high?
2025-08-15 08:49
Trending Topics
View More2.29K Popularity
32.92K Popularity
44.32K Popularity
10.39K Popularity
8.29K Popularity
Pin
Strike Gold by Sharing Your TradFi Orders and Pictures!
Post on Gate Square and split $10,000 in rewards!
The TradFi Gold Lucky Bag is now live—1g of real gold every 10 minutes. Trade nonstop, win nonstop!
👉 https://www.gate.com/announcements/article/49357
🎁 50 lucky winners × $200 Position Vouchers ($10 × 20 leverage)
How to Join:
1️⃣ Post your order on Square with #GateTradFi1gGoldGiveaway, including:
A trade or draw screenshot
A brief experience sharing
2️⃣ Or create a related image (AI creation allowed) with a short promo line, such as:
Get gold on Gate App — 1g every 10 minutes!
⏰ Jan 2Gate Square New & Returning Creator Rewards are ongoing!
Your ideas may be more valuable than you think!
Make your first post or come back post to share a $20,000 monthly prize pool!
Post with #MyFirstPostOnSquare to receive a $50 Position Voucher each
Monthly Top Posters and Top Engagers will each earn an extra $50 reward
Your crypto insights could inspire many—start creating today!
👉 https://www.gate.com/postGate Square “Creator Certification Incentive Program” — Recruiting Outstanding Creators!
Join now, share quality content, and compete for over $10,000 in monthly rewards.
How to Apply:
1️⃣ Open the App → Tap [Square] at the bottom → Click your [avatar] in the top right.
2️⃣ Tap [Get Certified], submit your application, and wait for approval.
Apply Now: https://www.gate.com/questionnaire/7159
Token rewards, exclusive Gate merch, and traffic exposure await you!
Details: https://www.gate.com/announcements/article/47889
Innovent Biologics: Positive Results from Phase II Clinical Trial of Innovative Drug ICP-488
Jinshi data news on October 9th, Norcheng Jianhua announced in the evening that the company’s innovative drug ICP-488 achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. The results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvement in PASI75 at week 12 compared to patients receiving placebo. In addition, the proportion of patients receiving ICP-488 treatment who achieved PASI90, PASI100, and static Physician Global Assessment (sPGA) 0/1 (i.e., complete or near-complete clearance of skin lesions) was significantly higher than that in the placebo group.